Congress quietly extends regulatory relief for billion-dollar startups

What it does

This bill raises the revenue threshold for 'emerging growth companies' from $1 billion to $3 billion and extends the period during which they qualify for reduced regulatory burdens from 5 years to 10 years. Emerging growth companies face lighter disclosure and auditing requirements under federal securities law; the bill makes it easier for larger, longer-lived startups to retain that lighter regulatory treatment.

Why we flagged it

The bill's sole operative mechanism is to expand and extend the emerging growth company exemption—a regulatory carve-out that reduces disclosure, audit, and compliance burdens. It is a straightforward deregulatory measure, not a hidden rider or complex restructuring.

What the text implies

• Companies with $1B–$3B in revenue can now claim emerging growth status for up to 10 years instead of 5, delaying the point at which they must comply with full Sarbanes-Oxley auditing and disclosure standards.
• Investors in these larger, longer-lived companies will receive less frequent and less rigorous financial audits, potentially masking deteriorating financial conditions or accounting irregularities.
• The bill may reduce the pool of companies subject to full SEC disclosure rules, lowering overall market transparency and increasing information asymmetry between insiders and public shareholders.
• Venture-backed and private-equity-backed companies can remain in the lighter regulatory regime longer, potentially delaying the point at which their financial condition becomes fully visible to public markets.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill extends regulatory relief to larger companies for longer periods, reducing transparency and audit rigor that protect public investors. Investors in these companies face weaker disclosure requirements and less rigorous audits, increasing information asymmetry and fraud risk. The primary beneficiaries are the companies themselves (lower compliance costs), not the investing public.

Who stands to gain

• growth-stage private companies with $1B–$3B revenue
• venture capital and private equity firms (portfolio companies face lower compliance costs)
• accounting and audit firms (reduced audit scope = lower costs for clients)

Named in the bill

Securities and Exchange Commission (SEC), Securities Act of 1933, Securities Exchange Act of 1934, emerging growth companies, Sarbanes-Oxley Act (referenced implicitly via audit standards)

Where it stands

2 cosponsors: 1 Democrats, 1 Republicans.

• May 13, 2025 — Introduced · Congress.gov: “Introduced in House”
• May 13, 2025 — Referred to House Committee on Financial Services · Congress.gov: “Referred to the House Committee on Financial Services”
• May 20, 2025 — Markup held in committee · Congress.gov: “Committee Consideration and Mark-up Session Held”
• May 20, 2025 — Reported out of committee · Congress.gov: “Ordered to be Reported (Amended) by the Yeas and Nays: 31 - 20”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $20,320,000 in lobbying spend. A filing names 164 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Bryan Steil, the sponsor, reported $1,735,700 in PAC receipts in the 2026 cycle.

• Chamber of Commerce of the U.S.A. — $17,960,000 on 1 filing
• Biotechnology Innovation Organization — $2,360,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.